CN111041098A - Application of reagent for detecting proline-rich and frizzled 2A expression level and kit - Google Patents
Application of reagent for detecting proline-rich and frizzled 2A expression level and kit Download PDFInfo
- Publication number
- CN111041098A CN111041098A CN201910656953.6A CN201910656953A CN111041098A CN 111041098 A CN111041098 A CN 111041098A CN 201910656953 A CN201910656953 A CN 201910656953A CN 111041098 A CN111041098 A CN 111041098A
- Authority
- CN
- China
- Prior art keywords
- prrc2a
- breast cancer
- detecting
- expression level
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of biology, and relates to application of a reagent for detecting PRRC2A expression level and a kit. More particularly, the application of the reagent for detecting the PRRC2A expression level in the preparation of a preparation for the auxiliary diagnosis of breast cancer and/or the prognosis of a breast cancer patient and a kit for the auxiliary diagnosis of breast cancer and/or the prognosis of a breast cancer patient. The detection result of a clinical sample shows that the expression of PRRC2A in the breast cancer is obviously increased compared with that of a tissue beside the cancer; and PRRC2A high expression is not beneficial to the overall survival of breast cancer patients. Therefore, the reagent for detecting the change of the gene expression can be used for the prognosis or diagnosis and treatment of the breast cancer.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to application of a reagent for detecting the expression level of proline-rich and frizzled 2A (PRRC2A) in preparation of a preparation for auxiliary diagnosis of breast cancer and/or prognosis of a breast cancer patient, and a kit for auxiliary diagnosis of breast cancer and/or prognosis of a breast cancer patient.
Background
Breast cancer is the most common malignancy in women, with up to 170 million breast cancer patients newly diagnosed worldwide each year, with approximately 522000 deaths from breast cancer, second only to lung cancer, on 2012 epidemiological statistics in developed countries. Breast cancer accounts for 25% of all female tumors, and 15% of all tumor-associated deaths. In China, 278800 new breast cancer cases are detected in 2013, the morbidity is 42.02/100000 according to the standard of Chinese population, the estimated death number is 64600, and the mortality is 9.74/100000. The incidence and mortality of breast cancer are increasing in China with the change of social and economic factors. With the understanding of the biological mechanism of the occurrence and development of breast cancer, tumor targeted therapy, endocrine therapy and the like play an important role in the treatment of breast cancer. With the development of molecular typing and precise medicine, the research and discovery of new key target genes of breast cancer have important significance for the individualized diagnosis and treatment of breast cancer.
Disclosure of Invention
The invention aims to provide a novel breast cancer prognostic marker rich in proline and frizzled 2A (PRRC2A), and further provides application of a reagent for detecting the expression level of PRRC2A in preparation of a preparation for auxiliary diagnosis of breast cancer and/or prognosis of a breast cancer patient and a kit for auxiliary diagnosis of breast cancer and/or prognosis of the breast cancer patient.
PRRC2A is a protein-coding Gene, located at 6p21.33, containing 31 exons, Gene ID:7916, which encodes a protein that is localized to the cell membrane, nucleus and cytoplasm. At present, no report is found about the role of PRRC2A gene in the development of breast cancer. The inventor discovers that PRRC2A high expression is unfavorable for the prognosis of breast Cancer patients through high-throughput data mining of Cancer Genome Atlas (TCGA), and further verifies the prognostic effect of PRRC2A expression difference on the breast Cancer patients through collecting clinical breast Cancer patient samples and follow-up information.
In order to achieve the above objects, the first aspect of the present invention provides a use of a reagent for detecting the expression level of proline-rich and frizzled 2A (PRRC2A) in the preparation of a preparation for breast cancer auxiliary diagnosis and/or breast cancer patient prognosis.
Further, the detecting the PRRC2A expression level comprises detecting the gene expression level of PRRC2A and/or detecting the protein expression level of PRRC 2A.
More specifically, the method for detecting the expression level of PRRC2A comprises the following steps: detecting the expression level of PRRC2A in breast cancer and paracarcinoma tissues by an RT-qPCR method; detecting the expression level of PRRC2A mRNA in breast cancer and paracarcinoma tissues by a molecular probe technology; the PRRC2A protein expression quantity in breast cancer and paracarcinoma tissues is detected by immunohistochemistry or Western-Blot.
More specifically, the reagent for detecting the expression level of PRRC2A is an oligonucleotide probe targeting a PRRC2A coding DNA sequence, a PCR primer or an antibody targeting PRRC 2A.
According to the present invention, preferably, the reagent for detecting the expression level of PRRC2A is a nucleic acid having the sequence shown in SEQ ID NO: 1 and SEQ ID NO: 2 in the presence of a primer for real-time fluorescent quantitative PCR.
5’-GATCTGCCATCCCCTTCGGA-3’，SEQ ID NO：1
5’-GCCCACAGGTAACAGAGAAAG-3’，SEQ ID NO：2
The second aspect of the present invention provides a kit for breast cancer auxiliary diagnosis and/or breast cancer patient prognosis, which comprises: a reagent for detecting the expression level of PRRC 2A.
Further, the reagent for detecting the expression level of PRRC2A is an oligonucleotide probe targeting PRRC2A coding DNA sequence, a PCR primer, or an antibody targeting PRRC 2A.
Specifically, the reagent for detecting the expression level of PRRC2A is a reagent with the nucleotide sequence shown in SEQ ID NO: 1 and SEQ ID NO: 2 in the presence of a primer for real-time fluorescent quantitative PCR.
According to the present invention, the kit may further contain other conventional reagents for real-time fluorescence quantification, and preferably, the kit further comprises at least one of the following components: trizol, isopropanol, chloroform, absolute ethanol, RNase-free water, random primers, 5 XM-MLV buffer, dNTPs, RNase inhibitor, M-MLV reverse transcriptase, a primer having the sequence of SEQ ID NO: 3 and SEQ ID NO: 4, and (4) ACTB real-time fluorescence quantitative PCR specific primers of the nucleotide sequence shown in the specification.
5’-GGCACCCAGCACAATGAAGA-3’，SEQ ID NO：3
5’-ACTCCTGCTTGCTGATCCAC-3’，SEQ ID NO：4
The detection result of a clinical sample shows that the expression of PRRC2A in the breast cancer is obviously increased compared with that in a para-carcinoma tissue (P < 0.001); and PRRC2A high expression is detrimental to the overall survival of breast cancer patients (P ═ 0.0259). Therefore, the reagent for detecting the change of the gene expression can be used for the prognosis or diagnosis and treatment of the breast cancer.
Additional features and advantages of the invention will be set forth in the detailed description which follows.
Drawings
The above and other objects, features and advantages of the present invention will become more apparent by describing in more detail exemplary embodiments thereof with reference to the attached drawings.
Fig. 1 shows TCGA high throughput data analysis of PRRC2A expression in breast cancer. PRRC2A expression was significantly higher in breast cancer tissues than in normal tissues (P < 0.001).
FIG. 2 shows TCGA high throughput data analysis of the effect of high expression of PRRC2A on survival in breast cancer patients. High PRRC2A expression was detrimental to overall survival in breast cancer patients (P < 0.001).
Fig. 3 shows the expression of PRRC2A in breast cancer tissue. PRRC2A expression was significantly higher in breast cancer tissues than in paracarcinoma tissues (P < 0.001).
Figure 4 shows the effect of high PRRC2A expression in breast cancer tissue on survival of breast cancer patients. High PRRC2A expression is detrimental to overall survival in breast cancer patients (P ═ 0.0259).
Detailed Description
Preferred embodiments of the present invention will be described in more detail below. While the following describes preferred embodiments of the present invention, it should be understood that the present invention may be embodied in various forms and should not be limited by the embodiments set forth herein. The examples, in which the specific conditions are not specified, were conducted under the conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
Example 1
This example demonstrates TCGA high throughput data analysis of PRRC2A expression changes in breast cancer.
TCGA high throughput data analysis process:
log-in TCGA Portal website UALCAN ((TM))http://ualcan.path.uab.edu/index.html) First page, click on "Analysis", enter the gene name "PRRC 2A", select TCGA dataset "Breast invasivechicoma", search, click on "Expression", record the result. And (3) mapping by using GraphPad 12.0 software, wherein the statistical method is T test, and the difference is statistically significant when P is less than 0.05.
2. As a result: PRRC2A expression was significantly elevated in breast cancer tissues compared to normal tissues (P <0.001), as shown in fig. 1.
Example 2
This example illustrates the relationship between high expression of PRRC2A and breast cancer prognosis in TCGA high throughput data analysis.
TCGA high throughput data analysis process:
the TCGA portal site cBioPortal (http:// www.cbioportal.org /), the tumor dataset "Breast Invasive Carcinoma (TCGA Provisional)" was selected, the omics dataset "mRNA Expression z-scenes (RNA Seq V2 RSEM)" was selected, the gene input "PRRC 2A: and EXP > 2 ', searching, clicking ' survivval ' in a pop-up page, and recording a result. The Kaplan-Meier method draws a survival curve, and log-rank tests the difference of the survival curve, wherein the difference has statistical significance when P is less than 0.05.
2. As a result: high PRRC2A expression was detrimental to overall survival in breast cancer patients (P <0.001) (fig. 2).
Example 3
This example illustrates the preparation of reagents for detecting the expression level of PRRC2A for preparing a kit (50 reactions) for the prognosis of breast cancer patients.
1.Trizol 50.0ml；
2. 50.0ml of isopropanol;
3. 50.0ml of chloroform;
4. 50.0ml of absolute ethyl alcohol;
5. RNase-free water 5.0ml
6.1.0. mu.M Random primers (Random primers) 50.0. mu.l;
7.5 XM-MLV buffer 2.0 ml;
8.10.0 mM deoxynucleotide triphosphate (dNTPs) 100.0. mu.l;
9.40U/. mu.l RNase inhibitor 50.0. mu.l;
10.200U/. mu. l M-MLV reverse transcriptase 50.0. mu.l;
11.ABI 2×PCR Mix 2.0ml；
12.10.0 μ M PRRC2A real-time fluorescent quantitative PCR specific primer 30.0 μ l, the primer sequence is shown in Table 1;
13.10.0 μ M ACTB real-time fluorescent quantitation PCR specific primers 30.0 μ l, the primer sequences are shown in Table 1.
TABLE 1 fluorescent quantitative RT-PCR primer sequences
Example 4
This example illustrates the detection of PRRC2A in a clinical breast cancer tissue sample.
1. The study was performed with patient informed consent. Clinical information from 57 breast cancer patients was obtained from patient visit records. Breast cancer specimens are divided into two parts: one fraction was immediately frozen in liquid nitrogen and stored at-80 ℃ until RNA extraction, and the other fraction was used for histopathological evaluation.
2. Extraction of total RNA from tissues: the experiment was performed in an ice bath. Placing 30-50 mg of tissue (fresh or tissue preserved at-70 ℃ in liquid nitrogen) into a 1.5ml centrifuge tube, adding 1ml Trizol, homogenizing fully, and standing at room temperature for 5 min; adding 200 μ l chloroform into each tube, mixing vigorously for 30sec, standing for 15min, and centrifuging at 4 deg.C and 12000rpm for 15 min; gently sucking 400 μ l of the supernatant liquid into another new centrifuge tube, adding isopropanol with the same volume, gently inverting and mixing, and centrifuging at 12000rpm at 4 ℃ for 10 min; discarding the supernatant, adding 1ml of 75% alcohol to wash the precipitate, and centrifuging at 4 ℃ and 12000rpm for 10 min; the supernatant was discarded as much as possible, air-dried at room temperature for 10min, and dissolved by adding 10. mu.l of RNase-free water to each tube (10-15 min. lysis-promoting at 65 ℃). OD260 was measured and the RNA concentration was calculated.
RNA(mg/ml)＝40×OD260X dilution multiple (n)/1000
3. Reverse transcription: each 25. mu.l reverse transcription system contained 100pmol of random primer, 2. mu.g of total RNA, 1. mu.l of M-MLV reverse transcriptase, 0.625. mu.l of RNase inhibitor, 1.25. mu.l of dNTPs (10mM), 5. mu.l of 5 XM-MLV buffer, and a 25. mu.l of RNase-free water. The reaction conditions are as follows: 1h at 37 ℃ and 5min at 95 ℃.
4. Quantitative PCR: each 20. mu.l reaction system contained 2 XPCR Mix 10. mu.l, upstream and downstream primers 0.4. mu.l each, cDNA 1. mu.l, ddH2O8.2. mu.l. The reaction conditions are as follows: 94 ℃ for 2min, 94 ℃ for 15s, 60 ℃ for 40s, 40 cycles.
5. 2-ΔΔCTCalculating the relative expression quantity of PRRC 2A: the experiment detects the relative expression change of PRRC2A in 57 breast cancer tissues and 18 paracarcinoma tissues. ACTB as reference gene, and the target gene PRRC2A C determined by qPCRTC of reference gene ACTB with the same value as that of the tissue sourceTSubtracting the values to obtain Δ CTThen, Δ C is addedTAnd control group Δ CTSubtracting to obtain Δ Δ CT(taking a paracarcinoma sample Δ CTHas an average value of Δ CTControl), and calculating the relative expression of PRRC2A in each group by using the Power function in the Excell table. Differential expression, P, of PRRC2A between breast and paracarcinoma was analyzed using a software GraphPad Prism 6.0 mapping, T-test<A difference of 0.05 is statistically significant.
High PRRC2A expression and prognosis in breast cancer patients: the follow-up time of the patients is 1-32 months, and the number of successfully received follow-up patients is 57. PRRC2A showed high expression in the case of 2-fold higher relative expression than that in the paracarcinoma tissues, 9 cases, while PRRC2A showed low expression in the other cases, 47 cases. The Kaplan-Meier method draws a survival curve, and log-rank tests the difference of the survival curve, wherein the difference has statistical significance when P is less than 0.05.
7. As a result:
the detection result of a clinical sample shows that the expression of PRRC2A in the breast cancer is obviously increased compared with that in a para-carcinoma tissue (P <0.001), as shown in figure 3; and PRRC2A high expression is detrimental to overall survival of breast cancer patients (P ═ 0.0259), as shown in fig. 4.
Having described embodiments of the present invention, the foregoing description is intended to be exemplary, not exhaustive, and not limited to the embodiments disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments.
Sequence listing
<110> Jiangsu medical profession college
<120> application of reagent for detecting proline-rich and frizzled 2A expression level and kit
<130>BJI1900784JSYY
<160>4
<170>SIPOSequenceListing 1.0
<210>1
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>1
<210>2
<211>21
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
gcccacaggt aacagagaaa g 21
<210>3
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>3
<210>4
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
Claims (9)
1. The application of the reagent for detecting the expression level of proline-rich and frizzled 2A (PRRC2A) in preparing a preparation for auxiliary diagnosis of breast cancer and/or prognosis of breast cancer patients.
2. The use of claim 1, wherein the detecting the expression level of PRRC2A comprises detecting the gene expression level of PRRC2A and/or detecting the protein expression level of PRRC 2A.
3. The use of claim 1, wherein the method of detecting the expression level of PRRC2A comprises: detecting the expression level of PRRC2A in breast cancer and paracarcinoma tissues by an RT-qPCR method; detecting the expression level of PRRC2A mRNA in breast cancer and paracarcinoma tissues by a molecular probe technology; the PRRC2A protein expression quantity in breast cancer and paracarcinoma tissues is detected by immunohistochemistry or Western-Blot.
4. The use of claim 1, wherein the reagent for detecting the expression level of PRRC2A is an oligonucleotide probe targeting a DNA sequence encoding PRRC2A, a PCR primer, or an antibody targeting PRRC 2A.
5. The use according to claim 4, wherein the reagent for detecting the expression level of PRRC2A is a reagent with the sequence shown in SEQ ID NO: 1 and SEQ ID NO: 2 in the presence of a primer for real-time fluorescent quantitative PCR.
6. A kit for use in breast cancer assisted diagnosis and/or prognosis of a breast cancer patient, the kit comprising: a reagent for detecting the expression level of PRRC 2A.
7. The kit of claim 6, wherein the reagent for detecting the expression level of PRRC2A is an oligonucleotide probe targeting a DNA sequence encoding PRRC2A, a PCR primer, or an antibody targeting PRRC 2A.
8. The kit according to claim 7, wherein the reagent for detecting the expression level of PRRC2A is a reagent having the sequence shown in SEQ ID NO: 1 and SEQ ID NO: 2 in the presence of a primer for real-time fluorescent quantitative PCR.
9. The kit of claim 6, wherein the kit further comprises at least one of the following components: trizol, isopropanol, chloroform, absolute ethanol, RNase-free water, random primers, 5 XM-MLV buffer, dNTPs, RNase inhibitor, M-MLV reverse transcriptase, a primer having the sequence of SEQ ID NO: 3 and SEQ ID NO: 4, and (4) ACTB real-time fluorescence quantitative PCR specific primers of the nucleotide sequence shown in the specification.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910656953.6A CN111041098B (en) | 2019-07-19 | 2019-07-19 | Application of reagent for detecting proline-rich and frizzled 2A expression level and kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910656953.6A CN111041098B (en) | 2019-07-19 | 2019-07-19 | Application of reagent for detecting proline-rich and frizzled 2A expression level and kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111041098A true CN111041098A (en) | 2020-04-21 |
| CN111041098B CN111041098B (en) | 2021-11-30 |
Family
ID=70232345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910656953.6A Active CN111041098B (en) | 2019-07-19 | 2019-07-19 | Application of reagent for detecting proline-rich and frizzled 2A expression level and kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111041098B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114431193A (en) * | 2021-12-14 | 2022-05-06 | 中国人民解放军军事科学院军事医学研究院 | Application of Prrc2b in preparation of medicine for treating demyelinating diseases |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101065501A (en) * | 2004-11-24 | 2007-10-31 | 弗·哈夫曼-拉罗切有限公司 | Method for determining genotoxicity |
| CN103451272A (en) * | 2012-05-31 | 2013-12-18 | 益善生物技术股份有限公司 | BAT3 gene mutation detection specific primer and liquid phase chip |
| CN106868105A (en) * | 2015-09-16 | 2017-06-20 | 应诺美鑫有限公司 | Chemotherapy Choice |
| US20180067117A1 (en) * | 2010-08-13 | 2018-03-08 | Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University | Biomarkers for the early detection of breast cancer |
-
2019
- 2019-07-19 CN CN201910656953.6A patent/CN111041098B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101065501A (en) * | 2004-11-24 | 2007-10-31 | 弗·哈夫曼-拉罗切有限公司 | Method for determining genotoxicity |
| US20180067117A1 (en) * | 2010-08-13 | 2018-03-08 | Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University | Biomarkers for the early detection of breast cancer |
| CN103451272A (en) * | 2012-05-31 | 2013-12-18 | 益善生物技术股份有限公司 | BAT3 gene mutation detection specific primer and liquid phase chip |
| CN106868105A (en) * | 2015-09-16 | 2017-06-20 | 应诺美鑫有限公司 | Chemotherapy Choice |
Non-Patent Citations (7)
| Title |
|---|
| HARIKRISHNA NAKSHATRI等: "Intrinsic subtype-associated changes in the plasma proteome in breast cancer", 《PROTEOMICS CLIN. APPL.》 * |
| NCBI: "GenBank登录号：NM_004638.4", 《NCBI GENBANK》 * |
| NCBI: "GenBank登录号：NM_080686.3", 《NCBI GENBANK》 * |
| Q. PAN等: "Association of MHC class III gene polymorphisms with ER-positive breast cancer in a Chinese Han population", 《GENETICS AND MOLECULAR RESEARCH》 * |
| RONG WU等: "A novel m6A reader Prrc2a controls oligodendroglial specification and myelination", 《CELL RESEARCH》 * |
| 佚名: "UALCAN analysis：PRRC2A/BAT2，TCGA dataset：Breast invasive carcinoma； cBioPortal：Breast Invasive Carcinoma（TCGA，PanCancer Atlas），mRNA Expression z-Scores（RNA Seq V2 RSEM），PRRC2A； TCGA cases：Breast，Project：TCGA-BRCA；", 《TCGA UALCAN CBIOPORTAL》 * |
| 潘琼等: "PRRC2A基因单核苷酸多态性与江苏省汉族女性散发性乳腺癌易感性的相关性研究", 《中国肿瘤临床》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114431193A (en) * | 2021-12-14 | 2022-05-06 | 中国人民解放军军事科学院军事医学研究院 | Application of Prrc2b in preparation of medicine for treating demyelinating diseases |
| CN114431193B (en) * | 2021-12-14 | 2022-10-25 | 中国人民解放军军事科学院军事医学研究院 | Application of Prrc2b in preparation of medicine for treating demyelinating diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111041098B (en) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109797219B (en) | Application of reagent for detecting ABRACL expression level and kit | |
| CN111041095B (en) | Application of reagent for detecting expression level of chromosome 8 open reading frame 73 and kit | |
| CN109852698B (en) | Application of reagent for detecting ring finger protein 32 expression level and kit | |
| CN111041098B (en) | Application of reagent for detecting proline-rich and frizzled 2A expression level and kit | |
| CN111041093B (en) | Application of reagent for detecting expression level of coiled coil domain protein 127 and kit | |
| TW201514311A (en) | Method for determining the prognosis of pancreatic cancer | |
| CN110273000B (en) | Application of reagent for detecting expression level of zinc finger protein 468 and kit | |
| CN111041097A (en) | Application of reagent for detecting expression level of open reading frame 76 of chromosome 8 and kit | |
| CN111041092A (en) | Application of reagent for detecting expression level of Fas associated factor family member 2 and kit | |
| CN111041099B (en) | Application of reagent for detecting expression level of G protein-coupled receptor 137B and kit | |
| CN111041094B (en) | Application of reagent for detecting expression level of TM2 structural domain protein 2 and kit | |
| CN110358830B (en) | Application of reagent for detecting expression level of open reading frame 53 of chromosome 8 and kit | |
| CN110358828B (en) | Application of reagent for detecting expression level of E3 SUMO protein transferase NSE2 and kit | |
| CN111041091B (en) | Application of reagent for detecting expression level of THUMP structural domain protein 3 and kit | |
| CN110358831B (en) | Application of reagent for detecting expression level of transmembrane protein 41A and kit | |
| CN110527727B (en) | Application of reagent for detecting zinc finger protein 28 expression level and kit | |
| CN110358832B (en) | Application of reagent for detecting expression level of PH domain family A member 6 and kit | |
| CN110358833B (en) | Application of reagent for detecting expression level of Tudor structural domain protein 2 and kit | |
| CN111041100A (en) | Application of reagent for detecting expression level of tetraspanin 17 and kit | |
| CN110358829A (en) | Detect application and the kit of the reagent of recombined human peptidyl prolyl cis-trans isomerase-H expression | |
| CN111041096A (en) | Application of reagent for detecting expression level of open reading frame 33 of chromosome 8 and kit | |
| CN114990217A (en) | Application of reagent for detecting expression level of chromosome 17 open reading frame 42 in skin melanoma | |
| CN114457164A (en) | Application of reagent for detecting expression level of chromosome 10 open reading frame 81 and kit | |
| CN114277153A (en) | Application of reagent for detecting expression level of ZFP92 and kit | |
| CN114262732A (en) | Application of reagent for detecting expression level of C11orf16 and kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220805 Address after: Plant No. 201 and 202, 2nd Floor, Building A1, Phase I, Changsha E Center, No. 18, Xiangtai Road, Liuyang Economic and Technological Development Zone, Changsha City, Hunan Province, 410300 Patentee after: Hunan Huaxi Pharmaceutical Co., Ltd. Address before: 224008 no.283, Jiefang South Road, Yancheng City, Jiangsu Province Patentee before: JIANGSU VOCATIONAL College OF MEDICINE |
|
| TR01 | Transfer of patent right |